Kura Oncology granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five new employees on July 1, 2026. The grants were approved by the Compensation Committee of the Company’s Board of Directors under the Company’s 2023 Inducement Option Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were approved as an inducement material to the employees’ employment.

Each stock option has an exercise price of $10.78 per share, which equals the closing price of the Company’s common stock on July 1, 2026. The options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date. The remaining shares will vest monthly over the subsequent 36 months, subject to the new employees’ continued service relationship with Kura Oncology through the applicable vesting dates.

The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms of an applicable stock option agreement covering the grant. Kura Oncology is a biopharmaceutical company focused on precision medicines for the treatment of cancer.

Grant Details

Kura Oncology reported $5.8 million in net product revenue for the first quarter of 2026, marking the first full quarter of commercial sales for Comzifty. The company recorded a net loss of $73.3 million for the period, compared to a net loss of $57.4 million in the prior year. Management highlighted that the early commercial performance exceeded expectations and positions the company to define leadership in the Menin inhibitor class over the next 12 to 24 months.

Financial Performance

The revenue generation was accompanied by increased operational expenses as the company advanced its clinical programs and commercial infrastructure. Research and development expenses rose to $65.3 million, up from $56 million in the first quarter of 2025. Selling, general, and administrative expenses increased to $31.6 million, compared to $22.8 million in the same period last year, driven by the commercial launch of Comzifty.

Collaboration revenue for the quarter was $12.5 million, a decrease from $14.1 million in the prior year. The company maintained its guidance for collaboration revenue, expecting it to range between $45 million and $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028.

Balance Sheet and Guidance

As of March 31, 2026, Kura Oncology held cash, cash equivalents, and short-term investments totaling $580.8 million. This figure compares to $667.2 million as of December 31, 2025. The company stated that its current cash position, combined with anticipated payments of $180 million under a collaboration agreement, is sufficient to fund operations through the first top-line Phase 3 results from the COMET-017 trial anticipated in 2027.

*As of December 31, 2025.

Operational and Clinical Updates

Commercial execution for Comzifty included 85 new patient starts and nearly 160 total prescriptions across approximately 60 activated accounts. Management noted strong enrollment in the COMET-017 trials, which are progressing ahead of plan. The company expects to present updated data from the Ziftomenib and 7+3 combination at the EHA meeting in June, as well as preliminary data from the Ziftomenib and gilteritinib combination in the second half of the year.